KUALA LUMPUR, Nov. 24 -- Parents in Malaysia now have access to Beyfortus (nirsevimab), a newly approved preventive treatment designed to protect newborns and infants from respiratory syncytial virus (RSV), a contagious virus that can cause serious respiratory illness in babies.

Developed by Sanofi and AstraZeneca, Beyfortus has been approved by the National Pharmaceutical Regulatory Agency (NPRA) and can be administered during a child's first year of life - either from birth or as early as possible - providing protection during their most vulnerable months.

Clinical trials have shown that a single dose of Beyfortus can reduce RSV-related hospitalisations by over 80 per cent in the first six months of life.

RSV remains a hidden public ...